We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+1.08%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.37B
AUM Growth
+$113M
Cap. Flow
+$184M
Cap. Flow %
13.39%
Top 10 Hldgs %
57.14%
Holding
78
New
18
Increased
12
Reduced
20
Closed
17

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$69.7M
2
ABBV icon
AbbVie
ABBV
+$66.1M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$52.5M
4
SYK icon
Stryker
SYK
+$43M
5
REPL icon
Replimune Group
REPL
+$37.7M

Top Sells

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$86.5M
2
ELAN icon
Elanco Animal Health
ELAN
+$51.7M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$19.3M
4
COGT icon
Cogent Biosciences
COGT
+$14.4M
5
INCY icon
Incyte
INCY
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLT icon
51
Bolt Biotherapeutics
BOLT
$7.63M
$1.47M 0.11%
137,722
– –
IRON icon
52
Disc Medicine
IRON
$2.85B
$1.44M 0.11%
22,752
-18,600
-45% -$1.08M
BDX icon
53
Becton Dickinson
BDX
$43.8B
$1.12M 0.08%
4,951
-10,240
-67% -$2.36M
VIR icon
54
Vir Biotechnology
VIR
$1.48B
$838K 0.06%
114,131
-15,115
-12% -$119K
ICUI icon
55
ICU Medical
ICUI
$4.04B
$776K 0.06%
+5,000
New +$846K
ELVN icon
56
Enliven Therapeutics
ELVN
$3.77B
$766K 0.06%
+34,025
New +$882K
IMA
57
ImageneBio Inc
IMA
$63.2M
$627K 0.05%
31,885
– –
TVTX icon
58
Travere Therapeutics
TVTX
$5.27B
$568K 0.04%
+32,616
New +$577K
GPCR icon
59
Structure Therapeutics
GPCR
$3.46B
$567K 0.04%
20,892
-17,900
-46% -$635K
LUNG icon
60
Pulmonx
LUNG
$51.5M
$416K 0.03%
61,326
-987
-2% -$6.5K
RNAM
61
DELISTED
Avidity Biosciences
RNAM
$401K 0.03%
13,789
-16,683
-55% -$697K
ATXS
62
DELISTED
Astria Therapeutics
ATXS
– –
-85,640
Closed -$943K
AXSM icon
63
PUT
Axsome Therapeutics
AXSM
$12.3B
– –
-150,000
Closed -$13.5M
CABA icon
64
Cabaletta Bio
CABA
$444M
– –
-1,533,883
Closed -$7.24M
CATX icon
65
Perspective Therapeutics
CATX
$322M
– –
-120,632
Closed -$1.61M
ELAN icon
66
Elanco Animal Health
ELAN
$12.7B
– –
-3,518,684
Closed -$51.7M
GH icon
67
Guardant Health
GH
$19.3B
– –
-406,645
Closed -$9.33M
ILMN icon
68
Illumina
ILMN
$28.7B
– –
-40,611
Closed -$5.3M
IMTXW
69
DELISTED
Immatics N.V. Warrants
IMTXW
– –
-366,568
Closed -$852K
KURA icon
70
Kura Oncology
KURA
$901M
– –
-296,884
Closed -$5.8M
NVO
71
Novo Nordisk
NVO
$220B
– –
-726,329
Closed -$86.5M
NVS icon
72
PUT
Novartis
NVS
$297B
– –
-200,000
Closed -$23M
PAHC icon
73
Phibro Animal Health
PAHC
$1.43B
– –
-238,184
Closed -$5.36M
RVMD icon
74
Revolution Medicines
RVMD
$40B
– –
-203,271
Closed -$9.22M
SLNO
75
PUT
DELISTED
Soleno Therapeutics
SLNO
– –
-300,000
Closed -$15.1M
1 2
3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2024 Portfolio in Review

As of Q4 2024, Sofinnova Investments held 78 positions worth $1.37B, up 9% from $1.26B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sofinnova Investments deployed $184M of net new capital in Q4 2024, opening 18 new positions and adding to 12 existing holdings. Its largest new stake was Gilead Sciences: 774,227 shares worth $71.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was IDEAYA Biosciences, an estimated $19.3M trimmed.

  • Sofinnova Investments's largest Q4 2024 buy was Gilead Sciences: 774,227 shares worth $71.5M.
  • Sofinnova Investments added most to Replimune Group in Q4 2024, an estimated $37.7M increase.
  • Sofinnova Investments's biggest Q4 2024 reduction was IDEAYA Biosciences, cutting an estimated $19.3M.
  • Sofinnova Investments fully exited Novo Nordisk in Q4 2024, selling an estimated $86.5M.
  • Sofinnova Investments's ten largest holdings make up 57% of its $1.37B portfolio in Q4 2024.
  • Sofinnova Investments opened 18 new positions and closed 17 in Q4 2024.
  • Sofinnova Investments's portfolio value rose 9% quarter-over-quarter to $1.37B.

Based on Sofinnova Investments's 13F filing for Q4 2024, filed 14 Feb 2025.